Epitope mapping. (a–c) Results of epitope mapping performed by competition BLI, comparing mAbs cloned from Ad26.COV2.S vaccinees 1.5 and 6 mo after vaccination (n = 33, each) to mAbs cloned from mRNA vaccinees at prime or 1.3 and 5 mo after Vax2 (Cho et al., 2021; Muecksch et al., 2022). Pie charts show the distribution of the antibody classes among all RBD-binding antibodies (a), Wuhan-Hu-1 neutralizing antibodies only (b), or nonneutralizing antibodies only (c). Statistical significance was determined by using a two-tailed χ2 test.
Figure 4.

Epitope mapping. (a–c) Results of epitope mapping performed by competition BLI, comparing mAbs cloned from Ad26.COV2.S vaccinees 1.5 and 6 mo after vaccination (n = 33, each) to mAbs cloned from mRNA vaccinees at prime or 1.3 and 5 mo after Vax2 (Cho et al., 2021; Muecksch et al., 2022). Pie charts show the distribution of the antibody classes among all RBD-binding antibodies (a), Wuhan-Hu-1 neutralizing antibodies only (b), or nonneutralizing antibodies only (c). Statistical significance was determined by using a two-tailed χ2 test.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal